Last reviewed · How we verify
NBMI
At a glance
| Generic name | NBMI |
|---|---|
| Sponsor | EmeraMed |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NBMI Treatment in Patients With Mercury Toxicity (PHASE2, PHASE3)
- Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) (PHASE2)
- Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation (PHASE2)
- Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication (PHASE2)
- NBMI - Clinical Study on COPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NBMI CI brief — competitive landscape report
- NBMI updates RSS · CI watch RSS
- EmeraMed portfolio CI